Claims for Patent: 6,565,879

Summary for Patent: 6,565,879

Title:	Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers
Abstract:	A method is provided for increasing the permeability of skin or mucosal tissue to a topically or transdermally administered pharmacologically or cosmeceutically active peptide, polypeptide or protein. The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the peptide, polypeptide or protein through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. Formulations and drug delivery devices employing hydroxide-releasing agents as permeation enhancers are provided as well.
Inventor(s):	Luo; Eric C. (Plano, TX), Jacobson; Eric C. (San Diego, CA), Hsu; Tsung-Min (San Diego, CA)
Assignee:	Dermatrends, Inc. (San Diego, CA)
Application Number:	09/687,937
Patent Claims:	1. A method for enhancing the flux of a peptidyl drug through a body surface of an individual so as to achieve therapeutically effective blood levels thereof, the method comprising administering a peptidyl drug and a predetermined amount of a hydroxide-releasing agent to the body surface of the individual, wherein the predetermined amount of the hydroxide-releasing agent is effective to provide a pH in the range of approximately 8.5 to 13 at the localized region of the body surface, during drug administration, and wherein the peptidyl drug and hydroxide-releasing agent are present in a formulation and the amount of hydroxide-releasing agent in the formulation applied to the body surface is the total of (a) the amount required to neutralize any acidic species in the formulation plus (b) an mount equal to approximately 0.25 wt. % to 7.0 wt. % of the formulation. 2. The method of claim 1, wherein the body surface is skin. 3. The method of claim 1, wherein the body surface is mucosal tissue. 4. The method of claim 1, wherein the formulation is a liquid or semi-solid formulation. 5. The method of claim 4, wherein the formulation is aqueous. 6. The method of claim 5, wherein the formulation has a pH in the range of approximately 8.5 to 13. 7. The method of claim 6, wherein the formulation has a pH in the range of approximately 8.5 to 11.5. 8. The method of claim 5, wherein the aqueous formulation is a cream or gel. 9. The method of claim 1, wherein the amount of hydroxide-releasing agent in the formulation is the total of (a) the amount required to neutralize any acidic species in the formulation plus (b) an amount equal to approximately 0.5 wt. % to 4.0 wt. % of the formulation. 10. The method of claim 9, wherein the amount of hydroxide-releasing agent in the formulation is the total of (a) the amount required to neutralize any acidic species in the formulation plus (b) an amount equal to approximately 0.75 wt. % to 2.0 wt. % of the formulation. 11. The method of claim 9, wherein the amount of hydroxide-releasing agent in the formulation is the total of (a) the amount required to neutralize any acidic species in the formulation plus (b) an amount equal to approximately 1.0 wt. % of the formulation. 12. The method of claim 1, wherein the peptidyl drug and hydroxide-releasing agent are administered by applying a drug delivery device to a predetermined area of a human patient's body surface, the device comprising the peptidyl drug and the hydroxide-releasing agent, and having an outer occlusive backing layer that serves as the outer surface of the device during use. 13. The method of claim 12, wherein the peptidyl drug and hydroxide-releasing agent are present in an adhesive, gel or liquid formulation contained within the device. 14. The method of claim 1, which further comprises pretreating the body surface with a pretreatment amount of the hydroxide-releasing agent prior to administering the peptidyl drug and hydroxide-releasing agent formulation. 15. The method of claim 14, wherein the pretreatment hydroxide-releasing agent is administered up to about 24 hours prior to administering the peptidyl drag and hydroxide-releasing agent formulation. 16. The method of claim 15, wherein the pretreatment hydroxide-releasing agent is administered up to about 15 hours prior to administering the peptidyl drug and hydroxide-releasing agent are present in a formulation. 17. The method of claim 16, wherein the pretreatment hydroxide-releasing agent is administered up to about 5 hours prior to administering the peptidyl drug and hydroxide-releasing agent are present in a formulation. 18. The method of claim 14, wherein the pretreatment hydroxide-releasing agent is administered to the body in the form of a solution comprised of approximately 0.25 wt. % to 7.0 wt. % of the hydroxide-releasing agent. 19. The method of claim 18, wherein the pretreatment hydroxide-releasing agent is administered to the body in the form of a solution comprised of approximately 0.5 wt. % to 4.0 wt. % of the hydroxide-releasing agent. 20. The method of claim 19, wherein the pretreatment hydroxide-releasing agent is administered to the body in the form of a solution comprised of approximately 0.75 wt. % to 2.0 wt. % of the hydroxide-releasing agent. 21. The method of claim 20, wherein the pretreatment hydroxide-releasing agent is administered to the body in the form of a solution comprised of approximately 1.0 wt. % of the hydroxide-releasing agent. 22. The method of claim 1, wherein the peptidyl drug is a peptide. 23. The method of claim 1, wherein the peptidyl drug is a polypeptide. 24. The method of claim 1, wherein the peptidyl drug is a protein. 25. The method of claim 1, wherein the peptidyl drug is selected from the group consisting of coagulation modulators, cytokines, endorphins, kinins, peptidyl hormones, LHRH analogues and combinations thereof. 26. The method of claim 25, wherein the peptidyl drug is a coagulation modulator. 27. The method of claim 26, wherein the peptidyl drug is selected from the group consisting of .alpha..sub.1 -antitrypsin, .alpha..sub.2 -macroglobulin, antithrombin III, factor I, factor II, factor III, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, heparin cofactor II, kallikrein, plasmin, plasminogen, prekallikrein, protein C, protein S, thrombomodulin and combinations thereof. 28. The method of claim 25, wherein the peptidyl drug is a cytokine. 29. The method of claim 28, wherein the peptidyl drug is selected from the group consisting of colony stimulating factor 4, heparin binding neurotrophic factor, interferon-.alpha., interferon .alpha.-2a, interferon .alpha.-2b, interferon .alpha.-n3, interferon-.beta., interferon-.gamma., interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, interleukin-13, interleukin-14, interleukin-15, interleukin-16, interleukin-17, tumor necrosis factor, tumor necrosis factor-.alpha., granuloycte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, midkine, thymopoietin and combinations thereof. 30. The method of claim 25, wherein the peptidyl drug is an endorphin. 31. The method of claim 30, wherein the peptidyl drug is selected from the group consisting of dermorphin, dynorphin, .alpha.-endorphin, .beta.-endorphin, .gamma.-endorphin, (.sigma.-endorphin [Leu.sup.5 ]enkephalin, [Met.sup.5 ]enkephalin, substance P, and combinations thereof. 32. The method of claim 25, the peptidyl drug is a kinin. 33. The method of claim 32, wherein the peptidyl drug is selected from the group consisting of bradykinin, potentiator B, bradykinin potentiator C, kallidin and combinations thereof. 34. The method of claim 25, wherein the peptidyl drug is a peptidyl hormone. 35. The method of claim 34, wherein the peptidyl drug is selected from the group consisting of activin, amylin, angiotensin, atrial natriuretic peptide, calcitonin, calcitonin gene-related peptide, calcitonin N-terminal flanking peptide, cholecystokinin, ciliary neurotrophic factor, corticotropin, corticotropin-releasing factor, epidermal growth factor, follicle-stimulating hormone, gastrin, gastrin inhibitory peptide, gastrin-releasing peptide, ghrelin, glucogon, gonadotropin-releasing factor, growth hormone releasing factor, human chorionic gonadotropin, inhibin A, inhibin B, insulin, leptin, lipotropin, luteinizing hormone, luteinizing hormone-releasing hormone, .alpha.-melanocyte-stimulating hormone, .beta.-melanocyte-stimulating hormone, .gamma.-melanocyte-stimulating hormone, melatonin, motilin, oxytocin, pancreatic polypeptide, parathyroid hormone, placental lactogen, prolactin, prolactin-release inhibiting factor, prolactin-releasing factor, secretin, somatotropin, somatostatin, thyrotropin, thyrotropin-releasing factor, thyroxine, triiodothyronine, vasoactive intestinal peptide, vasopressin and combinations thereof. 36. The method of claim 35, wherein the peptidyl drug is oxytocin. 37. The method of claim 25, wherein the peptidyl drug is an LHRH analogue. 38. The method of claim 37, wherein the peptidyl drug is selected from the group consisting of buserelin, deslorelin, fertirelin, goserelin, histrelin, leuprolide, lutrelin, nafarelin, tryptorelin and combinations thereof. 39. The method of claim 38, wherein the peptidyl drug is leuprolide. 40. The method of claim 1, wherein the peptidyl drug is selected from the group consisting of abarelix, adenosine deaminase, anakinra, ancestim, alteplase, alglucerase, asparaginase, bivalirudin, bleomycin, bombesin, desmopressin acetate, des-Q14-ghrelin, dornase-.alpha., enterostatin, erythropoeitin, exendin-4, fibroblast growth factor-2, filgrastim, .beta.-glucocerebrosidase, gonadorelin, hyaluronidase, insulinotropin, lepirudin, magainin I, magainin II, nerve growth factor, pentigetide, thrombopoietin, thymosin .alpha.-1, thymidin kinase, tissue plasminogen activator, tryptophan hydroxylase, urokinase, urotensin II and combinations thereof. 41. The method of claim 1, wherein the hydroxide-releasing agent is selected from the group consisting of inorganic hydroxides, inorganic oxides, metal salts of weak acids, and mixtures thereof. 42. The method of claim 41, wherein the hydroxide-releasing agent is an inorganic hydroxide. 43. The method of claim 42, wherein the inorganic hydroxide is selected from the group consisting of ammonium hydroxide, alkali metal hydroxides, alkaline earth metal hydroxides, and mixtures thereof. 44. The method of claim 43, wherein the inorganic hydroxide is selected from the group consisting of ammonium hydroxide, sodium hydroxide, calcium hydroxide, potassium hydroxide, magnesium hydroxide, and mixtures thereof. 45. The method of claim 44, wherein the inorganic hydroxide is sodium hydroxide. 46. The method of claim 44, wherein the inorganic hydroxide is potassium hydroxide. 47. The method of claim 41, wherein the hydroxide-releasing agent is an inorganic oxide. 48. The method of claim 47, wherein the inorganic oxide is selected from the group consisting of magnesium oxide, calcium oxide, and mixtures thereof. 49. The method of claim 41, wherein the hydroxide-releasing agent is a metal salt of a weak acid. 50. The method of claim 49, wherein the metal salt of a weak acid is selected from the group consisting of sodium acetate, sodium carbonate, tribasic sodium phosphate, dibasic sodium phosphate, sodium borate, potassium carbonate, potassium acetate, dibasic potassium phosphate, tribasic potassium phosphate, sodium metaborate, and mixtures thereof.

Details for Patent 6,565,879

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2019-12-16
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2019-12-16
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2019-12-16
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2019-12-16